Advinus unveils early promise of glucokinase activator for diabetes
This article was originally published in Scrip
Executive Summary
Advinus Therapeutics of India has unveiled the first Phase I details of its glucokinase activator compound, GKM-001, for diabetes, which it believes may have benefits over other molecules in the class.